Oramed Pharmaceuticals Inc Dossier - Source-backed chat

Oramed Pharmaceuticals Inc

ORMPNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.11

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.48Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $183.3M

Enterprise Value $168.1M

Shares Outstanding 41.8M diluted

Moat Rating None

Next Earnings Date16 Nov 2026

Last ex-dividend16 Jan 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Oramed Pharmaceuticals has transitioned from a pure-play clinical-stage biotech to an active operator of a medical technology portfolio. Following the failure of its Phase 3 trial for oral insulin (ORMD-0801) in Type 2 Diabetes, the company pivoted by transferring its Protein Oral Delivery (POD) technology platform to Lifeward in exchange for a 49.9% beneficial ownership stake and a 4% royalty on ReWalk franchise net sales. While Oramed's Q1 2026 results showed a massive swing to profitability ($38.3M net income) driven by fair value gains on investments (Alpha Tau, Scilex) and capital gains from the Lifeward IP transfer, its core operations still generated an operating loss of $3.7M with zero product revenue. The company's future value is heavily tied to Lifeward's commercial execution, the performance of its diversified investment portfolio (including real estate-backed loans), and the success of a narrower, targeted Phase 2 trial for ORMD-0801 in high-responder T2D subgroups.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.25

Mean target$6.25

High · most bullish analyst$6.25

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Lifeward struggles with commercial execution of its medical robotics franchise, resulting in minimal royalty payments to Oramed. The targeted Phase 2 trial for ORMD-0801 faces delays or fails to show clinical significance. Volatility in the public markets leads to large fair value write-downs on Oramed's investment holdings, eroding its asset base.

Base CaseCentral scenario

Lifeward successfully integrates the POD technology and maintains steady sales growth of its ReWalk and AlterG systems, providing Oramed with stable royalty streams. The narrower Phase 2 trial for ORMD-0801 in high-responder subgroups commences smoothly. Oramed's diversified investment portfolio remains stable, preserving its book value.

Bull CaseUpside scenario

Oramed's transition to a medical technology holding company model unlocks significant value from its diversified investment portfolio (including Alpha Tau and Scilex). Furthermore, the strategic transaction with Lifeward Ltd. to commercialize its Protein Oral Delivery (POD) technology platform provides Oramed with a 49.9% equity stake in Lifeward, aligning it with a commercial-stage partner to drive long-term upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Substantial asset backing with $238.3M in stockholders' equity and a diversified portfolio of strategic investments (Alpha Tau, Lifeward, real estate-backed loans).
Downside protection provided by a 4% royalty stream on Lifeward's established ReWalk franchise net sales.
Retained upside in the oral insulin program (ORMD-0801) through a planned, highly targeted Phase 2 trial in high-responder patient subgroups.

Key Investment Risks

Core operations remain pre-revenue and unprofitable, with a $3.7M operating loss in Q1 2026.
High dependence on the commercial success and execution of Lifeward (medical robotics) rather than Oramed's own direct operations.
Earnings quality is highly volatile, as net income is driven primarily by non-operating mark-to-market investment adjustments.

Thesis Invalidation Triggers

Failure to initiate or achieve positive clinical data in the upcoming targeted Phase 2 trial for ORMD-0801.
A severe commercial downturn or operational failure at Lifeward, neutralizing the expected royalty and equity value.
Significant write-downs in the value of the Alpha Tau or real estate investment portfolios.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.